Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. - Wikidata - awgldk - TriplyDB

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.

http://www.wikidata.org/entity/Q34166561

about

How does the efficacy and safety of Oralair(®) compare to other products on the market?New era of biologic therapeutics in atopic dermatitis Update on the performance and application of basophil activation tests Basic science for the clinician: Mechanisms of sublingual and subcutaneous immunotherapy.Lung-derived innate cytokines: new epigenetic targets of allergen-specific sublingual immunotherapy.Sublingual immunotherapy: World Allergy Organization position paper 2013 update.Epigenetics and development of food allergy (FA) in early childhood.International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem.Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).Oral and sublingual immunotherapy.Regulatory T cells and their roles in immune dysregulation and allergy.Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma.DNA methylation changes separate allergic patients from healthy controls and may reflect altered CD4+ T-cell population structure.Environmental assessment and exposure control of dust mites: a practice parameter.Sublingual Immunotherapy for Asthma: Affects T-Cells but Does not Impact Basophil Activation Characterization of CD4+ T cell subsets in allergy.Structural biology of mite allergens.Progress in understanding the epigenetic basis for immune development, immune function, and the rising incidence of allergic disease.Sublingual immunotherapy: current concepts for the U.S. practitioner.Immune mechanisms of sublingual immunotherapy.Selection of patients for sublingual versus subcutaneous immunotherapy.A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair).Updating the role played by immunotherapy for allergic rhinitis: meta-analysis.The future of biologics: applications for food allergy.Immunotherapy in all aspects.The Future of Sublingual Immunotherapy in the United States.Effect of allergen-specific immunotherapy on CD4+ T cells Epigenetics and allergy: from basic mechanisms to clinical applications.Grass pollen immunotherapy: where are we now.Epigenetic Changes During Food-Specific Immunotherapy.Allergen immunotherapy (AIT) for the multiple-pollen sensitive patient.Expanding Diversity and Common Goal of Regulatory T and B Cells. II: In Allergy, Malignancy, and Transplantation.Spectrum of T-lymphocyte activities regulating allergic lung inflammation.Multiallergen-specific immunotherapy in polysensitized patients: where are we?Initial immunological changes as predictors for house dust mite immunotherapy response.Modulation of Peanut-specific humoral and cellular responses pre- and post-oral immunotherapy.Synchronous Immune Alterations Mirror Clinical Response During Allergen Immunotherapy.Should we encourage allergen immunotherapy during pregnancy?EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis.Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma.

P2860

Q26745596-05584DDC-8938-4FC4-8642-E164916C3B36 Q27001941-916457CB-A897-45A9-B8D7-D10C419163C6 Q28280148-334B9FD9-E321-470F-A49A-0B6FEFA3A42E Q30276174-128C540B-B259-4977-B82D-CD619E4C4FD3 Q30359565-8A1CC686-9266-4CE5-9FFE-E1BA8F1FAC64 Q30440195-C6F50755-6612-46A4-9E98-99B2FEF3A537 Q33358887-4D6E9BD3-2ED1-4BF0-9793-737049F34C32 Q33572979-A5EABEA6-4029-4525-9881-BA50C10FF390 Q33999649-14AC0728-B08D-4371-8D36-B710C856A5D5 Q34044108-E1E7E384-4A52-4208-999D-6CC78517DE13 Q34166571-2963F358-556C-4952-9FE9-2A4AB19C2BC2 Q34375745-8394D269-D579-45DB-8DAA-9EF21C154E45 Q35082246-2A96CEFD-B597-4999-B943-B15A6F082BB4 Q37503322-DD0E8EC2-E287-4D13-931F-C0808F4CF0C8 Q37653676-76CB0DB8-DEFB-4B6B-8C48-EA3A41DBE627 Q38034308-73E360D5-EBA2-4631-8F97-DE17903FBB43 Q38051086-848F877B-6EB0-45A8-87E2-15C683669FA7 Q38051180-DF6D41A3-597F-4B3E-82D9-BA0F16019389 Q38245585-5264CCD7-9679-43A6-B80D-5078852D96F2 Q38246584-E884077F-FCC1-4ECB-8EFE-30A8636094C1 Q38257644-63F7AEAE-B662-42FC-9F11-A8BE869D7F62 Q38262772-19955A7A-6274-4A02-9CBA-31CE5AD2AF94 Q38271427-AADF547F-9FC4-44E2-9892-76EA1D22B5C5 Q38348057-74895436-326C-48A7-9BB5-BCCD702E224C Q38352179-324909B0-356B-4A6E-BE4A-997316C5CBA5 Q38543371-ACFD9AFB-EF48-4A10-A3D9-139C5AF70D3D Q38618287-C5600342-4870-427F-9EA0-AD6A1EB67612 Q38742430-9A165E0B-C1A1-41DD-88AA-F01F96740376 Q38773340-608080D6-B1E3-4429-BE72-81BFF23E71A8 Q38784112-4CB1A6BA-E635-49DC-A6FB-737870A3B3FC Q38968310-46B58EC4-3885-4C54-9FE8-98AC63C4DE3A Q39282520-EB0BBCE0-8842-4166-BE2E-F9DE092A9E77 Q39402895-506BC6D1-E07C-47B7-BF4E-BF02B8CCE133 Q39466603-A4608EE5-8834-4126-9372-8008CCC55F0F Q42477747-9494FABA-46D9-4E51-8516-78D7CFD41A02 Q45015033-43053262-41FA-462C-8BBB-A181F13DA322 Q45072722-957D1E29-15F4-43B7-BA32-90FB81E73BEB Q46117759-1B79B81B-40DC-469D-B3F9-FAEC958D100E Q47764778-658B82BA-52E1-47A9-A809-A4E16771166E Q47943200-B84B93A9-CA68-4395-BB42-13870A2FFB4F

P2860

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.

http://www.wikidata.org/entity/Q34166561

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@ast

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@en

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@nl

type

label

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@ast

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@en

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@nl

prefLabel

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@ast

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@en

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@nl

P1433

Q34166561-07932CD2-5C6E-4CFA-AA03-41F6F7BF07B9

P1476

Q34166561-3BAD0B07-9093-493E-8EFA-64A5C4C6E22A

P2093

Q34166561-0C454F40-3B14-42CD-96AC-EEC78E9467AD

Q34166561-479A3CF4-DB15-476D-B6B2-50C216DD84FC

Q34166561-4EB093E8-6846-4C50-9500-77167D126310

Q34166561-6B61A03D-A705-456C-A46F-62873ECE3A9C

Q34166561-76DCFD12-7CE0-4F94-AAD2-5FC8FD7C2161

Q34166561-A0EAFCD2-8192-4C36-964C-145D81259931

Q34166561-B11695A9-5EE2-4093-B899-5E481DB189A7

Q34166561-E8BE1C23-D3DC-4A20-83FB-B0572FB3638A

Q34166561-FB072EDC-0E2F-4915-A215-46EE89988610

Q34166561-FCE0C87C-6EFB-43A9-BD6E-9A0938982D51

P2860

Q34166561-03A8CF22-C86B-4AC6-A13D-3FC23BF402D3

Q34166561-03AE06F3-A586-4AA3-8982-35A036710A2E

Q34166561-04893698-68F5-494C-9FAF-19DEF0AE6F36

Q34166561-0688E577-E9B3-4DCE-8FCF-FF45F8022F09

Q34166561-096F3C3E-6FAA-4771-9CD1-8F6258CD7B62

Q34166561-0CF8308A-1D44-450B-8820-9E5A1B5B7069

Q34166561-2F11A5C5-043F-4498-AC6B-D895CA78F7FB

Q34166561-2F1ACA03-3E0A-4196-9168-E8175AC9B1AD

Q34166561-32703D89-FAB9-4B09-B476-4E0F1600E464

Q34166561-45479C3A-0047-46B0-802E-A040D4A43A64

P304

Q34166561-381E2DD1-81B2-42DF-A415-00F9FE5C84F2

P31

Q34166561-AE9324DA-E378-4FD9-8B42-D1A7E37B029B

P356

Q34166561-B3F2BEF3-9B5E-4331-880A-A2177423558A

P407

Q34166561-523B03E5-A88F-4607-A071-6D1089A95C08

P433

Q34166561-787CB3AB-1CAF-466D-8AA1-8CC0084FE831

P478

Q34166561-E5AD35EC-F432-4E19-B42E-48E955E5B33A

P577

Q34166561-2CD25FA0-6C68-4493-B48C-BD20C8FB929F

P698

Q34166561-F022388C-7F21-4D3B-B0EE-E6849461D7CE

P921

Q34166561-F6921AEF-0108-4F70-8E0D-90D6F13BD8DB

P932

Q34166561-37D6E28E-D069-45B8-B0C2-7F93E5D4B10D

P356

J.JACI.2012.04.021

P1433

The Journal of Allergy and Clinical Immunology

P1476

Epigenetic modifications and i ...... dual sublingual immunotherapy.

@en

P2093

Carah B Santos

http://www.w3.org/2001/XMLSchema#string

Elisabeth G Hoyte

http://www.w3.org/2001/XMLSchema#string

Fuad M Baroody

http://www.w3.org/2001/XMLSchema#string

Kari C Nadeau

http://www.w3.org/2001/XMLSchema#string

Marco A Garcia

http://www.w3.org/2001/XMLSchema#string

Neha Reshamwala

http://www.w3.org/2001/XMLSchema#string

Peter H Hwang

http://www.w3.org/2001/XMLSchema#string

Ravi S Swamy

http://www.w3.org/2001/XMLSchema#string

Soujanya Vissamsetti

http://www.w3.org/2001/XMLSchema#string

Tessa Hunter

http://www.w3.org/2001/XMLSchema#string

P2860

Control of regulatory T cell development by the transcription factor Foxp3

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis

FOXP3+ regulatory T cells in the human immune system

Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.

Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials.

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis.

Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns.

Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue.

Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy

P304

215-24.e7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACI.2012.04.021

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22677046

http://www.w3.org/2001/XMLSchema#string

P921

P932

4161455

http://www.w3.org/2001/XMLSchema#string